{"id":"NCT01146834","sponsor":"Weill Medical College of Cornell University","briefTitle":"Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma","officialTitle":"A Prospective Randomized Trial Comparing Three Different Peripheral Stem Cell Mobilization Regimens in Patients With Symptomatic Multiple Myeloma or Lymphoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03","primaryCompletion":"2019-02-04","completion":"2019-02-04","firstPosted":"2010-06-22","resultsPosted":"2019-12-17","lastUpdate":"2019-12-27"},"enrollment":47,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"bortezomib (Velcade)","otherNames":["Velcade"]},{"type":"DRUG","name":"cyclophosphamide","otherNames":["Cytoxan"]},{"type":"DRUG","name":"G-CSF","otherNames":["Filgrastim","Neupogen"]},{"type":"DRUG","name":"Plerixafor","otherNames":["Mozobil"]}],"arms":[{"label":"Arm A: VELCADE, CYCLOPHOSPHAMIDE, & G-CSF","type":"EXPERIMENTAL"},{"label":"Arm B: VELCADE & G-CSF","type":"EXPERIMENTAL"},{"label":"Arm C: CYCLOPHOSPHAMIDE & G-CSF","type":"EXPERIMENTAL"},{"label":"Arm D: PLERIXAFOR & G-CSF","type":"EXPERIMENTAL"},{"label":"Arm E: PLERIXAFOR, VELCADE, & G-CSF","type":"EXPERIMENTAL"}],"summary":"This phase III randomized trial compares three different peripheral stem cell mobilization regimens for patients with multiple myeloma who have received primary induction therapy or other therapies. Up to 180 patients will be enrolled. Patients eligible for treatment will be randomized to one of the three following mobilization regimens:\n\nArm A = VELCADE, CYCLOPHOSPHAMIDE, \\& G-CSF Arm B = VELCADE \\& G-CSF Arm C = CYCLOPHOSPHAMIDE \\& G-CSF Arm D = PLERIXAFOR \\& G-CSF Arm E = PLERIXAFOR, VELCADE, \\& G-CSF","primaryOutcome":{"measure":"Number of Patients Able to Collect >=6 x 106 CD34+ Cells/kg in <= 2 Collections.","timeFrame":"36 months","effectByArm":[{"arm":"Arm A: VELCADE, CYCLOPHOSPHAMIDE, & G-CSF","deltaMin":11,"sd":null},{"arm":"Arm B: VELCADE & G-CSF","deltaMin":0,"sd":null},{"arm":"Arm C: CYCLOPHOSPHAMIDE & G-CSF","deltaMin":14,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.90"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":11},"locations":{"siteCount":5,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":20},"commonTop":["Platelet count decreased","Anemia","White blood cell count decreased","Fatigue","Neutrophil count decreased"]}}